Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
No COA or purity below 90% is a hard disqualifier
What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy
Because your body does not readily store excess amounts, toxicity from B12 is very unlikely, even at the higher doses used in injections
Caldini, R
Much more research is yet to be conducted on the various other antioxidants, both to determine their therapeutic potential and to assess any potential adverse health impacts
The research points to a compound that helps the body heal faster and more completely from injury
US$ 26.17
US$ 22.48
US$ 27.88
US$ 28.06
US$ 23.07
US$ 25.84
US$ 20.63
